Company Overview of VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of small molecule product candidates. It develops Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases; and VTX-2337, a small molecule TLR8 agonist to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells. The company’s products also include VTX-1463, a TLR8 agonist administered intra-nasally for the treatment of seasonal and perennial allergies; and TLR8 antagonists for autoimmune diseases, including rheumatoid arthritis. VentiRx Pharmaceutica...
1191 Second Avenue
Seattle, WA 98101
Founded in 2006
Key Executives for VentiRx Pharmaceuticals, Inc.
Co-Founder, Chief Executive Officer, President and Director
Vice President of Finance and Administration
Vice President of Research
Compensation as of Fiscal Year 2014.
VentiRx Pharmaceuticals, Inc. Key Developments
VentiRx Pharmaceuticals, Inc. Announces Fast Track Designation Granted for Motolimod (VTX-2337)
Sep 2 14
VentiRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. Motolimid is a novel TLR8 immunotherapy currently being evaluated in two randomized, placebo-controlled Phase 2 trials. FDA Fast Track Designation is designed to facilitate frequent interactions with the FDA review team to expedite clinical development and submission of a New Drug Application (NDA) for drugs with the potential to treat serious or life-threatening conditions and address unmet medical needs. VentiRx has completed enrollment of over 290 patients in the GOG-3003 randomized, placebo-controlled Phase 2 trial of motolimod in combination with PLD in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. The study is being performed in collaboration with the Gynecologic Oncology Group (GOG) Partners Program. The primary endpoint of the study is overall survival. In April 2014, the FDA granted Orphan Drug designation to motolimod (VTX- 2337) for the treatment of ovarian cancer.
VentiRx Pharmaceuticals, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 10:45 AM
Jun 11 14
VentiRx Pharmaceuticals, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 10:45 AM. Venue: Washington State Convention Center, Seattle, Washington, United States.
VentiRx Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 09:30 AM
Jun 2 14
VentiRx Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 09:30 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Robert M. Hershberg, Co-Founder, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 22, 2014